Angiogenesis is the growth of new blood vessels.
The Center for Therapeutic Angiogenesis, under the direction of Princeton cardiologist Farrell Mendelsohn, M.D., is dedicated to performing research in the area of cardiovascular diseases to evaluate medications that stimulate the angiogenesis process.
Atherosclerosis is a major cause of death in the United States. It begins with the accumulation of cholesterol in the wall of arteries, eventually leading to the formation of plaque. Significant plaque build-up can lead to obstructed blood vessels, such as those leading to the heart (coronary artery disease or CAD) or those leading to the legs and feet (peripheral arterial disease or PAD).
The drugs that are being studied are meant to stimulate the growth of new blood vessels to improve the circulation to an area that is currently blocked by atherosclerosis to "trick" the body into making its own bypass. The research protocols vary according to the clinical aspect being studied. The Center for Therapeutic Angiogenesis at Princeton is one of the leading sites in the nation in this area of research and treats patients from all over the nation with severe heart disease and peripheral vascular disease.
For more information about current studies, call 205-780-4330, extension 234, email Director Susan DeRamus at firstname.lastname@example.org or visit http://www.CenterforTherapeuticAngiogenesis.org.